Indeed, in the fifth edition of World Health Organization (WHO) classification of Thoracic Tumors, the community of pathologists recognized this newly described entity but changed its name from SMARCA4-deficient thoracic sarcomas to SMARCA4-UT.6 Clinically, the majority of SMARCA4-UT shared an aggressive clinical course with a median overall survival (OS) between 4 and 7 months.1,7-11 Mostly male adults around 45 years old with a heavy smoking history are affected. The gene discussed is SMARCA4; the disease is neoplasm of thorax.